These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 21951990)

  • 21. Rethinking the role of long-acting atypical antipsychotics in the community setting.
    Altamura AC; Aguglia E; Bassi M; Bogetto F; Cappellari L; De Giorgi S; Fagiolini A; Ferrannini L; Girardi P
    Int Clin Psychopharmacol; 2012 Nov; 27(6):336-49. PubMed ID: 22859065
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment effectiveness and adherence in patients with schizophrenia treated with risperidone long-acting injection.
    Chang CL; Tzeng DS; Lung FW
    Psychiatry Res; 2010 Nov; 180(1):16-9. PubMed ID: 20488552
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Partial compliance in schizophrenia and the impact on patient outcomes.
    Llorca PM
    Psychiatry Res; 2008 Nov; 161(2):235-47. PubMed ID: 18849080
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Lifelong relapse prevention with antipsychotics in schizophrenia].
    Hasan A; Wobrock T
    Psychiatr Prax; 2010 Sep; 37(6):268-70. PubMed ID: 20803409
    [No Abstract]   [Full Text] [Related]  

  • 25. Relapse prevention and recovery in the treatment of schizophrenia.
    Schooler NR
    J Clin Psychiatry; 2006; 67 Suppl 5():19-23. PubMed ID: 16822093
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dosing issues and depot medication in the maintenance treatment of schizophrenia.
    Kane JM
    Int Clin Psychopharmacol; 1995 Sep; 10 Suppl 3():65-71. PubMed ID: 8866767
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of long-acting risperidone in psychiatric disorders: focus on efficacy, safety and cost-effectiveness.
    Keith S
    Expert Rev Neurother; 2009 Jan; 9(1):9-31. PubMed ID: 19102665
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Challenges in the design and conduct of controlled clinical effectiveness trials in schizophrenia.
    Rosenheck RA; Krystal JH; Lew R; Barnett PG; Thwin SS; Fiore L; Valley D; Huang GD; Neal C; Vertrees JE; Liang MH;
    Clin Trials; 2011 Apr; 8(2):196-204. PubMed ID: 21270143
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nonadherence to antipsychotic treatment in patients with schizophrenic disorders.
    Svestka J; Bitter I
    Neuro Endocrinol Lett; 2007 Feb; 28 Suppl 1():95-116. PubMed ID: 17262005
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia.
    Leucht S; Heres S
    J Clin Psychiatry; 2006; 67 Suppl 5():3-8. PubMed ID: 16822090
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Why do patients with schizophrenia who have poor insight still take antipsychotics? Memory deficits as moderators between adherence belief and behavior.
    Staring AB; van der Gaag M; Duivenvoorden HJ; Weiden PJ; Mulder CL
    J Psychiatr Pract; 2011 Sep; 17(5):320-9. PubMed ID: 21926527
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antipsychotic medication in the treatment of schizophrenia.
    Kane JM
    Isr J Psychiatry Relat Sci; 1995; 32(1):30-7. PubMed ID: 7542642
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novelty seeking and medication adherence in patients with schizophrenia.
    Aukst Margetić B; Jakovljević M; Ivanec D; Tošić G; Margetić B
    Psychiatry Res; 2011 Mar; 186(1):141-3. PubMed ID: 20630601
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The case for long-acting antipsychotic agents in the post-CATIE era.
    Nasrallah HA
    Acta Psychiatr Scand; 2007 Apr; 115(4):260-7. PubMed ID: 17355516
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Survey of medication adherence in patients with schizophrenia--Korean ADHES data.
    Kim SW; Yoon JS; Choi SK
    Hum Psychopharmacol; 2006 Dec; 21(8):533-7. PubMed ID: 17133616
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of patient and clinician perspectives in the assessment of antipsychotic medication adherence.
    Barbui C; Kikkert M; Mazzi MA; Becker T; Bindman J; Schene A; Nosè M; Helm H; Thornicroft G; Tansella M
    Psychopathology; 2009; 42(5):311-7. PubMed ID: 19672133
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Simplifying adherence in schizophrenia.
    Hardeman SM; Harding RK; Narasimhan M
    Psychiatr Serv; 2010 Apr; 61(4):405-8. PubMed ID: 20360281
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Strategies for improving treatment adherence in schizophrenia and schizoaffective disorder.
    Goff DC; Hill M; Freudenreich O
    J Clin Psychiatry; 2010; 71 Suppl 2():20-6. PubMed ID: 21190649
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Switching to long-acting injectable risperidone is beneficial with regard to clinical outcomes, regardless of previous conventional medication in patients with schizophrenia.
    Marinis TD; Saleem PT; Glue P; Arnoldussen WJ; Teijeiro R; Lex A; Latif MA; Medori R
    Pharmacopsychiatry; 2007 Nov; 40(6):257-63. PubMed ID: 18030649
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Qualitative inquiry into motivators for maintaining medication adherence among Taiwanese with schizophrenia.
    Chang YT; Tao SG; Lu CL
    Int J Ment Health Nurs; 2013 Jun; 22(3):272-8. PubMed ID: 22882876
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.